CYBB and colorectal carcinoma: In this study, we found that DADS treatment failed to increase the intracellular ROS levels and reversed the inhibition of GSK2795039 (an inhibitor of NADPH oxidase 2) on DNA damage, indicating that DADS treatment enhanced DNA damage in CRC cells, independent of elevating intracellular ROS levels.